Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIRS: Omiganan 1% Gel for Prevention of Catheter Site Infections
NCT00231153Phase 3Completed
- Sponsor
- Cadence Pharmaceuticals, Inc.
- Start
- Aug 2005
- Primary completion
- Jun 2008
- Countries
- 4
01
Overview
Phase 3, randomised, single-blind trial of CLS001 topical gel vehicle in catheter-associated urinary tract infection (CAUTI) (2 arms), sponsored by Cadence Pharmaceuticals, Inc. Primary endpoint: Local Catheter Site Infection. Started Aug 2005; status: completed.
02
Drugs
CLS001 topical gel vehicle
03
Conditions
catheter-associated urinary tract infection (CAUTI)
Beyond the preview
Go deeper on NCT00231153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231153.